HighTower Advisors LLC Sells 4,063 Shares of Amgen Inc. $AMGN

Key Points

• HighTower Advisors reduced its Amgen stake by 0.5%, selling 4,063 shares and retaining 816,257 shares valued at approximately $295.6 million. Institutional investors collectively own 76.5% of the company.
• Amgen exceeded quarterly expectations, reporting $6.29 in adjusted EPS and $10.05 billion in revenue, while revenue rose 9.5% year over year. The company issued 2026 EPS guidance of $22.30–$23.50 and pays an annualized dividend of $10.08 per share.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $381.68 price target. Positive developments include promising Repatha data and potential convenience advantages for obesity drug candidate MariTide, while Tavneos regulatory pressure and recent insider selling pose risks.

HighTower Advisors LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 816,257 shares of the medical research company's stock after selling 4,063 shares during the period. HighTower Advisors LLC owned approximately 0.15% of Amgen worth $295,583,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Groupe la Francaise raised its position in shares of Amgen by 647.8% during the second quarter. Groupe la Francaise now owns 1,361 shares of the medical research company's stock valued at $493,000 after buying an additional 1,179 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Amgen during the second quarter worth about $29,326,000. California State Teachers Retirement System increased its stake in Amgen by 36,047.1% during the second quarter. California State Teachers Retirement System now owns 298,255,793 shares of the medical research company's stock valued at $108,004,388,000 after acquiring an additional 297,430,677 shares during the period. Ameritas Advisory Services LLC raised its holdings in Amgen by 139.3% in the 2nd quarter. Ameritas Advisory Services LLC now owns 14,119 shares of the medical research company's stock valued at $5,113,000 after acquiring an additional 8,220 shares in the last quarter. Finally, Wedmont Private Capital raised its holdings in Amgen by 2.7% in the 2nd quarter. Wedmont Private Capital now owns 8,666 shares of the medical research company's stock valued at $3,149,000 after acquiring an additional 231 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Mizuho lifted their price objective on Amgen from $303.00 to $352.00 and gave the stock a "neutral" rating in a report on Tuesday, August 18th. Citigroup upped their target price on Amgen from $345.00 to $405.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. TD Cowen raised their target price on Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Wells Fargo & Company lifted their price target on shares of Amgen from $400.00 to $435.00 and gave the stock an "equal weight" rating in a research note on Friday. Finally, Wall Street Zen raised shares of Amgen from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $381.68.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company's stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. Insiders own 0.85% of the company's stock.

Amgen Price Performance

Amgen stock opened at $437.23 on Monday. The business has a 50 day simple moving average of $397.39 and a 200 day simple moving average of $367.14. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The company has a market capitalization of $236.38 billion, a PE ratio of 27.17, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. Amgen Inc. has a one year low of $269.77 and a one year high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen's dividend payout ratio is currently 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
• Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
• Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
• Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
• Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.